Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
ID: 357134Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357134

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-165.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models," aimed at supporting preclinical research on HIV/AIDS conducted by early-stage investigators with at least two years of postdoctoral experience. This funding initiative encourages innovative research approaches utilizing NHP models to develop next-generation therapies and strategies for HIV cure, aligning with the NIH Strategic Plan priorities for HIV research. Eligible applicants can request up to $200,000 in direct costs annually, with a total budget cap of $400,000 over two years, and must adhere to specific application procedures. The application deadline is September 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-165-Full-Announcement.html
    PAR-25-165.html
    The Department of Health and Human Services seeks applications for the Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate Models Grant, aimed at supporting preclinical research on HIV/AIDS by early-stage investigators with two years of postdoctoral experience. This funding opportunity encourages innovative approaches using nonhuman primates (NHPs) to develop next-generation therapies and strategies for HIV cure research. It aligns with the NIH Strategic Plan priorities and emphasizes the significance of NHPs as relevant models for advancing HIV/AIDS research. Eligible applicants include higher education institutions and non-profit organizations. Each application can request up to $200,000 in direct costs annually, with a total budget cap of $400,000 over two years. The opportunity does not permit clinical trials and requires detailed adherence to application procedures, including multiple necessary registrations for applicants. Key evaluation criteria include scientific merit, innovation, approach rigor, and investigator expertise. The NOFO underscores the importance of diverse research topics, including vaccine development and understanding CNS disease related to HIV. This initiative highlights the federal commitment to empower emerging researchers in addressing critical health challenges related to HIV/AIDS.
    Similar Opportunities
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research, aimed at providing ongoing support for breeding colonies of Specific Pathogen Free (SPF) macaques essential for HIV/AIDS research. The funding will facilitate the breeding, maintenance, and allocation of these macaques to qualified researchers, ensuring rigorous health and genetic monitoring to mitigate risks associated with certain viruses that could affect research outcomes. These colonies play a critical role in advancing studies related to vaccine development and co-infection, underscoring their importance in the fight against HIV/AIDS. Interested applicants, specifically public and state-controlled institutions of higher education, must submit their proposals by January 7, 2027, and can find further details and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)." This program aims to support early-stage investigators in developing their research careers over a maximum of five years, guided by experienced mentors specializing in the application of nonhuman primate (NHP) models in translational biomedical research. The initiative addresses the critical need for skilled researchers in areas such as infectious diseases and aging, emphasizing the importance of rigorous training and adherence to NIH policies. Eligible applicants must hold a relevant doctoral degree and be within ten years of obtaining it or completing residency. The NIH will provide financial support up to $75,000 per year for salaries and research expenses. Interested parties should submit their applications by January 7, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK." This funding initiative aims to support innovative pilot research projects that explore the biological, behavioral, and social mechanisms related to HIV pathogenesis, particularly focusing on comorbidities and complications affecting organs and tissues relevant to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The research is expected to enhance understanding of the interplay between HIV and associated health issues, with a funding cap of $275,000 over two years for successful applications. Interested applicants, including higher education institutions and various nonprofit organizations, should note that the application deadlines begin in April 2025, with the final submission date set for January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Implementation Science to End the HIV Epidemic
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Implementation Science to End the HIV Epidemic," aimed at advancing efforts to combat HIV through innovative research-community collaborations. The initiative seeks projects that will develop and evaluate strategies for HIV prevention, diagnosis, treatment, and outbreak response, particularly in communities disproportionately affected by the epidemic. This funding, totaling an estimated $7 million, will support approximately 10 awards, with applications open to a diverse range of eligible entities, including tribal governments, federal agencies, and community-based organizations. Interested applicants should note that the estimated synopsis close date is April 17, 2026, and the anticipated award date is December 1, 2026; for further inquiries, contact Rebecca Mandt, Ph.D., at rebecca.mandt@nih.gov or call 301-435-7695.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to HIV/AIDS within the National Institute on Deafness and Other Communication Disorders (NIDCD). This initiative encourages applications that address high-priority research areas identified by the NIH Office of AIDS Research, particularly focusing on the intersections of HIV/AIDS with hearing, communication, and associated disorders. Grants of up to $499,999 in direct costs are available for projects lasting up to five years, with no cost-sharing or matching requirements. Interested applicants, including educational institutions and community organizations, must adhere to NIH guidelines and submit their proposals through Grants.gov by the closing date of January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.